tbuckley/cabot-search huggingface dataset:
Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.
Authors: D. J. George, S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, A. J. Armstrong, R. J. Varley, J. Madden, J. W. Moul
Journal: Journal of Clinical Oncology (2011)

4664 Background: Sunitinib malate (Sutent, Pfizer) is an oral multi-targeted tyrosine kinase inhibitor of VEGF/PDGF receptors that may function in part to inhibit prostate tumor growth via anti-angiogenic mechanisms. Methods: We conducted a multi-site study of sunitinib in patients with newly diagnosed, clinically localized prostate cancer prior to prostatectomy. After meeting eligibility requirements (intermediate to high risk, localized prostate cancer, adequate laboratory parameters, no prior treatment for prostate cancer), subjects received sunitinib 50mg PO for 28 days followed by a 1 week washout period followed by either radical retropubic or robot-assisted prostatectomy. Pathologic specimens (pretreatment biopsies and prostatectomy specimens) were evaluated for apoptotic (TUNEL) and proliferation (Ki-67) indices, microvessel density (MVD) and gene expression patterns. Results: 31 subjects were enrolled (median age 60 yrs; ECOG=0, biopsy Gleason 3+4=7). Data analysis is complete for 28 subjects. Most common toxicities (>30%) were diarrhea, fatigue, hypertension, mucositis, neutropenia, taste alterations, and thrombocytopenia. Most common grade 3-4 toxicities (> 5%) were hypertension, increased AST/ALT, and neutropenia. Median PSA decline was 13.6% (range -32% to 80%). Median change in Ki-67 was -34% (lower quartile -64% upper quartile +1.3%); median change in TUNEL was 4.5% (lower quartile -76%, upper quartile +286%); and median change in MVD (CD31) was +22% (lower quartile -23%, upper quartile +110%). Gene expression analysis is ongoing. Conclusions: Sunitinib given in the pre-prostastectomy setting appears safe and tolerable with a similar toxicity profile seen in patients with advanced cancer. Changes in proliferation and apoptosis suggest a treatment effect, while increases in MVD suggest a possible rebound effect off of sunitinib.
Chronic Lymphocytic Leukemia: Correlations Between Oxidative Stress Metabolism and Cytogenetic Subgroups
Authors: Felix Carbonell, Isabel Oliver, Rosa Collado, Carmen Tormos, Antonio Iradi, Maite Orero, Concepción Cerda, Susana Beltran, Ana Del Rey, Amparo Miguel, Guillermo Sáez
Journal: Blood (2008)
0.1 Grams of Sub-Cutaneous Adipose Tissue (SCAT) as Source of Adult Multipotent Mesenchymal Stromal Cells (MSC) for Cell-Based Therapies.
Authors: Massimo Dominici, Rita Sternieri, Domenico De Fazio, Luigi Cafarelli, Giovanni Guaraldi, Carlotta Spano, Valeria Rasini, Paolo Paolucci, Michele Cilli, Federica Piccardi, Giuseppe Astori, Ted J. Hofmann, Edwin M. Horwitz, Pierfranco Conte
Journal: Blood (2007)
AB1121-HPR Quality of Life as A Criterion of Efficiency in Treatment of Patients with Osteoarthritis
Authors: M. Ramkhelawon, M. Myakishev, G. Suleymanova, R. Grekhoff
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To study the quality of life (QoL) of patients with osteoarthritis (OA), and how it changes depending on the clinical features of the disease and the psychological characteristics of the patients. <h3>Methods</h3> We examined 30 patients with OA prior and after treatment. For better comparisons, a control group was set up, which comprised of 30 residents of Volgograd city, in the same age range and sex and who did not suffer from serious somatic diseases. QoL was studied using the questionnaire "SF-36" (Ware JE, 1993). <h3>Results</h3> The QoL scores on all scales of the SF-36 questionnaire, in patients with OA were significantly lower than in the control group (p&lt;0.05). This showed the lowest scores in QoL osteoarthritis patients ever had before treatment. The physical activity in patients with OA was considerably affected due to the physical (p&lt;0.001) and role functioning (RF, RP) (p&lt;0.001), as well as indicators of somatic pain (BP) (p&lt;0.01). Factors that significantly impaired the physical component of QoL in patients with OA were: age of patients, stage of disease, the severity of joint pain on a visual analogue scale (VAS), and presence of clinically manifested anxiety (p&lt;0.05). Factors that significantly impaired social and psychological component of quality of life in OA patients were: stage and duration of the disease and increased functional insufficiency of the joints (p&lt;0.05). By improving the physical components of health (physical and role functioning, somatic pain) and psychological components (role emotional functioning, mental health) (p&lt;0.05), therapeutic measures significantly had a positive impact on the basic parameters of QoL in patients with OA. Role physical (RP) and role emotional (RE) functioning significantly changed by more than 42% (p&lt;0.001). The regularities were significantly associated with decreasing functional failure of the joints, decrease in the intensity of joint pain in VAS and decrease in ESR (p&lt;0.05). <h3>Conclusions</h3> Thus, after treatment, patients with OA had a significant improvement in physical health, noted by a reduction in pain and physical limitations, and, as a consequence, improved performance. The effectiveness of therapy in the hospital environment contributed in the formation of a positive subjective assessment of the health status in patients with OA. <h3>Disclosure of Interest</h3> None declared
PWE-049 Small-Bowel Capsule Endoscopy with 360° Panoramic-View: Results of The First Multicenter, Observational, Study
Authors: GE Tontini, F Wiedbrauck, F Cavallaro, R Marino, L Spina, ME McAlindon, A Koulaouzidis, E Rondonotti, L Pastorelli, M Vecchi
Journal: Gut (2016)

<h3>Introduction</h3> CapsoCam®SV (CapsoVision Inc, Saratoga, USA) is a new small bowel capsule (SBC) with "panoramic view", wire-free technology, and a long-lasting battery life. It is equipped with 4 high-frame rate cameras resulting in a high number of acquired frames. In previous studies, CapsoCam®SV showed comparable operative and diagnostic performance with frontal view SBCs.<sup>1,2</sup> <h3>Methods</h3> First multicenter study to assess the performance of CapsoCam®SV1 and SV2. Between January 2011 and November 2015, all consecutive patients undergoing SBC with CapsoCam® in 4 Italian, 2 British, and 1 German Institution(s) were included. Findings were classified according to their clinical significance, in line with Saurin classification, as P0: low probability; P1: intermediate probability; P2: high probability.<sup>3</sup> We defined SBC as "positive" when at least one P2 finding was identified. <h3>Results</h3> We enrolled 172 patients (94 M; median age±SD: 68±17 years, range: 9–97 years). Of them, 142 were referred for obscure GI bleeding (32 overt/110 occult OGIB) and 28 for suspected (17) or established (2) Crohn's disease (CD). Median battery life was 16.4 h (range 3.7–23.4 h). System failure occurred in 4 (2%) cases for technical problems; incomplete enteroscopy in 16/168 (9%), including two structuring disorders (i.e. stricturing CD &amp; SB adenocarcinoma) with spontaneous capsule excretion and one stricturing SB carcinoid with capsule retrieval at time of surgery.The ampulla of Vater was clearly identified in 34% cases. The overall diagnostic yield (DY; rate of positive tests) was 41%; 43% in OGIB and 30% in suspected CD. In a per-lesion analysis, overall 560 findings were detected (P0: 55, P1: 253, P2: 252). Most lesions were located in the small bowel (448/560: 80%); 48% of them were P2. Interestingly, 95/560 (17%) and 17/560 (3%) lesions were detected in the upper and in the lower GI tract, 34 and 12 of them being classified as P2, respectively. <h3>Conclusion</h3> The first multicenter study conducted in the everyday clinical practice with CapsoCam®SV, and based on the largest series so far collected, showed that SBC with 360° panoramic-view is easy to use, reliable, and has comparable DY and safety profile to forward view SCE. <h3>References</h3> 1 Friedrich K, <i>et al</i>. <i>J Gastroenterol Hepatol</i> 2013;<b>28</b>(9):1496–501. 2 Pioche M, <i>et al</i>. <i>Endoscopy</i> 2014;<b>46</b>(6):479–84. 3 Saurin JC, <i>et al</i>. <i>Endoscopy</i> 2003;<b>35</b>(7):576–84. <h3>Disclosure of Interest</h3> None Declared
Impact of Pre-Transplantation and Post-Transplantation Positron Emission Tomography (PET) Using 18-Fluorodeoxyglucose in Lymphoma Patients Treated with Autologous Stem Cell Transplantation.
Authors: Nicolas Mounier, Christian Gisselbrecht, Jean-Emmanuel Filmont, Xavier Cuenca, Laure Deville, Pauline Brice, Josette Briere, Eric De Kerviler, Jerome Larghero, Marjan Ertault, Christophe Hennequin, Jean-Luc Moretti
Journal: Blood (2006)
S28 Determinants of cough frequency in adult healthy volunteers
Authors: K Holt, C Gibbard, JA Smith
Journal: Thorax (2016)

<h3>Introduction</h3> Objective cough monitoring is a useful tool to investigate patterns of cough frequency and to evaluate novel cough treatments. The VitaloJAKTM (Vitalograph Ltd, UK) ambulatory cough monitor is a validated semi-automated system for the quantification of cough over 24 hours. Objective cough rates have yet to be quantified in large groups of healthy controls and the influences of subject factors are unclear. <h3>Objective</h3> To assess objective cough frequency in a large group of healthy adults across a range of ages. <h3>Method</h3> Objective 24 hour cough monitoring was performed using the VitaloJAKTM in adult healthy volunteers; those with a smoking history of &gt;20 pack years and &lt;6 months abstinence were excluded. The recordings were compressed using custom-written software and cough counted manually by trained cough counters and the daytime, night-time and total cough rates calculated. Daytime and total cough rates were log transformed for analysis. Independent t-tests (daytime and total) and Mann-Whitney U test (night-time) assessed the effect of gender and previous smoking. Spearmans correlation coefficients evaluated the relationships between cough frequency, age, BMI, and pulmonary function. <h3>Results</h3> Sixty healthy volunteers were recruited; 27 (45%) males, median age 40 yrs (range 20–74), median FEV<sub>1</sub> 103.0% predicted (81–141), median FVC 105.5% predicted (82–151), median BMI 24.6 kg/m2 (16.8–39.8), 48 (80%) of subjects had never smoked, median smoking history in the ex-smokers 2.9 (0.1–17) pack years. Median (IQR) 24 h cough rate was 0.17 c/h (0.05–0.87) with daytime rate of 0.26 c/h (0.63–1.35) and night-time rate of 0.00 c/h (0.00–0.12). Males coughed significantly more than females over 24hours [median 0.42 c/h (IQR 0.13–1.21) vs. 0.13 c/h (0.04–0.59), p = 0.038] and during the day [0.37 c/h (0.11–1.42) vs. 0.19 c/h (0.0–0.91), p = 0.036], but not during the night (p = 0.852). Cough frequency was not significantly correlated with age, BMI, FEV<sub>1</sub> or FVC. Cough frequency was no different between never and ex-smokers for daytime or 24 h (p = 0.46 and p = 0.20) but overnight was slightly lower for ex- than never smokers [median 0.00 c/h (0.00–0.09) vs. 0.12 c/h (0.0–0.64), p = 0.037]. <h3>Conclusions</h3> In healthy adults, spontaneous cough frequency is unaffected by age, BMI, and pulmonary function. Interestingly, males coughed more frequently than females, in contrast to our current knowledge of gender differences in cough reflex sensitivity.
AB1124-HPR Key Aspects of Health Professionals Required To Be Experts in Rheumatic Diseases (Reumappa)
Authors: M. Gobbo, L. Carmona
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Spanish Rheumatology League (Liga Reumatolόgica Española, LIRE) is developing an application for mobile devices and web browsers that incorporates a map of resources for rheumatic patients and professionals who treat them (Reumappa). This app helps locate with ease professionals and specialized services in rheumatic pathologies in Spain. A focus group with rheumatic patients was conducted in a previous phase in order to identify which fields of health professionals are required to manage their disease. It was then considered interesting to know whether there are relevant aspects of these specialties that distinguish professionals who can provide better care for rheumatic patients. <h3>Objectives</h3> To identify key issues that health professionals should have to bring added value in the management of rheumatic patients. <h3>Methods</h3> Focus Group with health professionals selected by patients as useful for the management of their disease (occupational therapist, physiotherapist, podiatrist, nurse, nutritionist, dentist, psychologist, and 2 social workers), sex (4 male, 5 female), age (3 &lt;45, 6&gt;45), years of professional experience (3 &lt;10, 6&gt;10), sector (5 private, 4 public). Key question: “<i>What aspects do you think add value to the care your specialty provides to rheumatic patients?</i>”. <h3>Results</h3> Table 1 shows the results of the focus group. N = nurse, SW = social worker, OT = occupational therapist, Nu = nutritionist, Po = podiatrist, Psi = psychologist, Phy = physiotherapist, D = dentist. <h3>Conclusions</h3> All health professionals who treat rheumatic patients should have at least a general knowledge of rheumatic diseases. Most health professionals should have a knowledge of drug treatments and recommended exercises. Nurses, psychologists, and physiotherapists require greater specialization to treat these patients. <h3>Disclosure of Interest</h3> None declared
AB0882 Acute Rheumatic Fever: A Ever Present Disease in The Western World with Possible Insidious Invalidating Heart Involvement
Authors: S. Pieropan, D. Degani, S. Picassi, I. Dal Forno, F. Caldonazzi, G. Piacentini, A. Boner, D. Biasi, S. Adami, M.A. Prioli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatic Fever (RF) is a systemic inflammatory disease following pharyngeal infection by goup A beta–hemolytic Streptococcus (GAS). <h3>Objectives</h3> to describe the characteristics of rheumatic Fever in a pediatric population of Verona between the 2005–2015. <h3>Methods</h3> Clinical presentation of 44 patients with diagnosis of Rheumatic Fever was investigated. Patient age, sex, age at diagnosis as well as Jones criteria fulfilled were reported. The presence/absence of familiarity of Rheumatic Fever, therapy prescibed, pophylaxis9 adhesion and primary cardiac involvement with it9s evolution after therapy were evaluated. <h3>Results</h3> Incidence of RF in Verona is increasing according to our data Age at diagnosis ranged from 2 to 17 years old (mean age 9-+4 years). Among Jones criteria carditis is most frequently encountered and its severity is not correlated with the values of antistreptolysin o titer (ASO). Heart murmur Was present in 57% of cases at diagnosis. 2 cases had a grade 1 AV blockade and two children underwent pacemaker implantation due to complete not reversibile AV blockade; no case of pericarditis was diagnosed and valvular involment (according to WHF classification) included mitral rigugitation (46,5%), aortic rigurgitation (7%) and bivalvular aortic-mitral rigurgitation (46.5%). <h3>Conclusions</h3> RF has not disappeared in the western world; cardiac involvement, which is not correlated with the absolute value of ASO, is the most worrysome clinical condition due to its possible severe sequaela; regular cardiac US and EKG togetherwith thorough physical examination should always be performed in order to identify subclincal cases. While prompt high dose steroids and NSAIDS administration prevent severe evolutions, antibiotics rappresent the main instrument in the primary and secondary prevention of the chronic reumatic Heart disease.Individual susceptabilty is a point of concern for the outbrake of RF as well as the need to identify "rheumatic" streptococci in order to elaborate a specific vaccination. <h3>Disclosure of Interest</h3> None declared
Increase of poorly proliferated p63<sup>+</sup>/Ki67<sup>+</sup> basal cells forming multiple layers in the aberrant remodeled epithelium in nasal polyps
Authors: L. Zhao, Y. Y. Li, C. W. Li, S. S. Chao, J. Liu, H. N. Nam, N. T. N. Dung, L. Shi, D. Y. Wang
Journal: Allergy (2016)

Aberrant epithelial remodeling with the ectopic expression of p63 (basal cell markers) is an important pathologic phenomenon seen in chronically inflamed airway epithelium such as in nasal polyps (NPs).Biopsies were obtained from 55 NP patients and 18 healthy controls (inferior turbinate). Among NP patients, 15 were treated with oral and nasal steroids, so that two sets of NP biopsies were taken before and after the treatments. p63, Ki67, type IV β-tubulin, and cell cycle markers were investigated in these specimens.The number of p63+ cells is significantly higher in both hyperplastic (1.53-fold, P < 0.0001) and squamous metaplastic (2.02-fold, P < 0.0001) epithelium from NPs than from healthy controls. There are three types of proliferative basal cells (p63+ /Ki67+ ) which are in different phases of the cell cycle, such as G1 phase (type I cells), S to G2 phase (type II cells), and mitosis (type III cells). Of importance, some type I cells may arrest after proliferation although they may still be p63+ /Ki67+ . In healthy epithelium, the ratio of the type I and II cells is almost 50:50. However, less type II cells are found in hyperplastic epithelium (34.85%, P = 0.012) and in squamous metaplastic epithelium (30.77%, P = 0.02) together with the presence of type III cells (3.45%, P = 0.01). These findings were not changed after steroid treatments.An increase of poorly proliferated basal cells forming multiple layers, which may stain for basal cell markers but does not form a proper epidermal barrier, is an important histopathologic phenomenon in aberrant remodeled epithelium of NPs.
Kras G12D Expression in Hematopoietic Stem/Progenitor Cells Initiates T Cell Acute Lymphoblastic Leukemia/Lymphoma.
Authors: Monique Dail, Qing Li, Jennifer Lauchle, Andrew McDaniel, Doris Kim, Keiko Akagi, Linda Wolff, Nancy Jenkins, Neil Copeland, Kevin Shannon
Journal: Blood (2007)
iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease
Authors: Zineb Sbihi, Antoine Dossier, David Boutboul, Lionel Galicier, Christophe Parizot, Amandine Emarre, Bénédicte Hoareau, Nicolas Dupin, Anne-Geneviève Marcelin, Anne Oudin, Claire Fieschi, Félix Agbalika, Brigitte Autran, Eric Oksenhendler, Guislaine Carcelain
Journal: Blood (2016)
Increased Expressions of Toll-Like Receptor 4 on Platelet Are Related to Type of Bacteria and Disease Severity in Patients with Sepsis
Authors: Liping Ma, Xiu-Ju Wang, Da-Nian Nie, Yi-Qing Li, Shuang-Fen Xie, Yu-Dan Wu, Cheng Zhang, Yin Song-Mei
Journal: Blood (2008)
Impact of Hepatic Toxicities on Survival after Allogeneic Hematopoietic Cell Transplantation (HCT): Comparison of Reduced-Intensity Versus Conventional Conditioning Regimens at a Single Center.
Authors: Atsushi Fujieda, Takahiro Fukuda, Fusako Ohara, Satoshi Yamasaki, Sungwon Kim, Shin-ichiro Mori, Ryuji Tanosaki, Yuji Heike, Atsushi Makimoto, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2006)
THU0321 The Association between Echocardiographic Parameters and Mortality in Patients with Lupus Nephritis
Authors: D.V. Monova, S. Monov, K. Kirilov, E. Peneva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease that affects multiple organs, with a broad spectrum of manifestations and a clinical status marked by periods of exacerbation and remission, with a variable course and prognosis. Cardiac abnormalities are common in lupus patients even when clinically asymptomatic from cardiac aspect. Echocardiography is an excellent non-invasive tool for cardiac evaluation. <h3>Objectives</h3> The aim of this study is to investigate the relationship between echocardiographic parameters and mortality in lupus nephritis (LN) patients. <h3>Methods</h3> A total of 258 LN patients who underwent echocardiography during year 1998–2015 were enrolled into this study. ln all patients a structural and functional cardiovascular alterations has been described. Association with all-cause and cardiac mortality were examined by the Cox proportional hazards model with adjustments for demographic factors, laboratory variables, medication use and echocardiographic parameters. <h3>Results</h3> The median duration of follow-up was 191,72 ± 82,54 months. The frequency of heart complications in LN patients is quite variable and depends on follow-up period. Among 258 LN patients, 94 (36,43%) died during the follow-up period. Of them, 44 patients (46,81%) died of cardiac disease. Disease duration of SLE and proteinuria were risk factors associated with the descent of E/A (E: the peak velocity at rapid left ventricular filling; A: the peak velocity during left atrial contraction) ratio (p&lt;0,05). In the multivariate analysis, the presence of cardiac manifestation, high systolic blood pressure (SBP) and serum level of C-reactive protein (CRP), low serum level of albumin, low estimated glomerular filtration rate (eGFR) and decreased left ventricular ejection fraction (LVEF) (p&lt;0,05) were independently associated with increased all-cause mortality. Meanwhile, factors correlated independently with an increase in cardiac mortality included the presence of cardiac manifestation, low eGFR, increased left ventricular mass index (LVMI) (p&lt;0,05) and decreased LVEF (p&lt;0,05). <h3>Conclusions</h3> Patients with LN have a higher risk of myocardial involvement, which can result in ventricular dysfunction. Decreased LVEF is associated with all-cause and cardiac mortality, whereas, increased LVMI is an independent risk factor for cardiac mortality in LN patients. These findings indicate the need for rigorous cardiac follow up in patients with LN. <h3>Disclosure of Interest</h3> None declared
Reduced Intensity Conditioning (RIC) Regimen of Alemtuzmab (A), Fludarabine (F), and Melphalan (M) for Transplantation of Pediatric Non-Malignant Hematologic Disorders (NMHD): Outcome Affected by Stem Cell Source.
Authors: Ka Wah Chan, Michael Grimley, Veronica H. Jude, Lisa McDonald, Julie Luke, Dennise Lim, Shalini Shenoy
Journal: Blood (2010)
I’ve got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells
Authors: Devin Dersh, Jonathan W. Yewdell
Journal: Journal of Clinical Investigation (2016)

CD8+ T cells play a central role in eradicating intracellular pathogens, but also are important for noninfectious diseases, including cancer and autoimmunity. The ability to clinically manipulate CD8+ T cells to target cancer and autoimmune disease is limited by our ignorance of relevant self-peptide target antigens. In this issue of the JCI, Pearson et al. describe 25,270 MHC class I-associated peptides presented by a wide range of HLA A and B allomorphs expressed by 18 different B cell lines. Via extensive bioinformatic analysis, the authors make surprising conclusions regarding the selective nature of peptide generation at the level of individual gene products and create a predictive algorithm for disease-relevant self-peptides that will be of immediate use for clinical and basic immunological research.
Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.
Authors: Sonia Vallet, Noopur Raje, MariaTeresa Fulciniti, Kenji Ishitsuka, Teru Hideshima, Klaus Podar, Samantha Pozzi, Iris Breitkreutz, Tanyel Kiziltepe, Yutaka Okawa, Hiroshi Ikeda, Loredana Santo, Siddhartha Mukherjee, Nileshwari Vaghela, Diana Cirstea, Mario Boccadoro, Kenneth C. Anderson
Journal: Blood (2007)
Von Willebrand Factor-Dependent Inflammatory Responses in Mouse Septic Model By Cecal Ligation and Puncture
Authors: Shogo Kasuda, Hideto Matsui, Shiro Ono, Yasunori Matsunari, Kenji Nishio, Midori Shima, Katsuhiko Hatake, Mitsuhiko Sugimoto
Journal: Blood (2014)